Acceptability and effectiveness of antimicrobial stewardship implementation strategies on fluoroquinolone prescribing

被引:4
作者
Suda, Katie J. [1 ,2 ]
Clore, Gosia S. [3 ,4 ]
Evans, Charlesnika T. [5 ,6 ]
Reisinger, Heather Schacht [3 ,4 ]
Kale, Ibuola [5 ]
Echevarria, Kelly [7 ]
Sherlock, Stacey Hockett [3 ,4 ]
Perencevich, Eli N. [3 ,4 ]
Goetz, Matthew Bidwell [8 ,9 ]
机构
[1] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15240 USA
[2] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA
[3] Univ Iowa, Dept Med, Carver Coll Med, Iowa City, IA USA
[4] Iowa City Vet Affairs VA Hlth Care Syst, Ctr Access & Delivery Res & Evaluat, Iowa City, IA USA
[5] Edward Hines Jr VA Hosp, Ctr Innovat Complex Chron Healthcare, Hines, IL USA
[6] Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Ctr Hlth Serv & Outcomes Res, Chicago, IL 60611 USA
[7] Pharm Benefits Management, Dept Vet Affairs, San Antonio, TX USA
[8] VA Greater Los Angeles Healthcare Syst, Dept Infect Dis, Los Angeles, CA 90073 USA
[9] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA
关键词
CLOSTRIDIUM-DIFFICILE INFECTION; HEALTH-CARE EPIDEMIOLOGY; ANTIBIOTIC STEWARDSHIP; DISEASES SOCIETY; GUIDELINES; PROGRAMS; AMERICA; DYSGLYCEMIA; SCOTLAND; UPDATE;
D O I
10.1017/ice.2021.10
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Objective: To assess the effectiveness and acceptability of antimicrobial stewardship-focused implementation strategies on inpatient fluoroquinolones. Methods: Stewardship champions at 15 hospitals were surveyed regarding the use and acceptability of strategies to improve fluoroquinolone prescribing. Antibiotic days of therapy (DOT) per 1,000 days present (DP) for sites with and without prospective audit and feedback (PAF) and/or prior approval were compared. Results: Among all of the sites, 60% had PAF or prior approval implemented for fluoroquinolones. Compared to sites using neither strategy (64.2 +/- 34.4 DOT/DP), fluoroquinolone prescribing rates were lower for sites that employed PAF and/or prior approval (35.5 +/- 9.8; P = .03) and decreased from 2017 to 2018 (P < .001). This decrease occurred without an increase in advanced-generation cephalosporins. Total antibiotic rates were 13% lower for sites with PAF and/or prior approval, but this difference did not reach statistical significance (P = .20). Sites reporting that PAF and/or prior approval were "completely" accepted had lower fluoroquinolone rates than sites where it was "moderately" accepted (34.2 +/- 5.7 vs 48.7 +/- 4.5; P < .01). Sites reported that clinical pathways and/or local guidelines (93%), prior approval (93%), and order forms (80%) "would" or "may" be effective in improving fluoroquinolone use. Although most sites (73%) indicated that requiring infectious disease consults would or may be effective in improving fluoroquinolones, 87% perceived implementation to be difficult. Conclusions: PAF and prior approval implementation strategies focused on fluoroquinolones were associated with significantly lower fluoroquinolone prescribing rates and nonsignificant decreases in total antibiotic use, suggesting limited evidence for class substitution. The association of acceptability of strategies with lower rates highlights the importance of culture. These results may indicate increased acceptability of implementation strategies and/or sensitivity to FDA warnings.
引用
收藏
页码:1361 / 1368
页数:8
相关论文
共 33 条
[1]  
[Anonymous], 2015, FORM MAN
[2]  
[Anonymous], 2016, FDA Drug Safety Communication: FDA review results in new warnings about using general anesthetics and sedation drugs in young children and pregnant women
[3]  
[Anonymous], 2000, PRINC SOUND DRUG FOR
[4]  
[Anonymous], 2019, FDA REINF SAF INF SE
[5]  
[Anonymous], 2018, FDA Warns About Increased Risk of Ruptures or Tears in the Aorta Blood Vessel With Fluoroquinolone Antibiotics in Certain Patients
[6]   Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America [J].
Barlam, Tamar F. ;
Cosgrove, Sara E. ;
Abbo, Lilian M. ;
MacDougall, Conan ;
Schuetz, Audrey N. ;
Septimus, Edward J. ;
Srinivasan, Arjun ;
Dellit, Timothy H. ;
Falck-Ytter, Yngve T. ;
Fishman, Neil O. ;
Hamilton, Cindy W. ;
Jenkins, Timothy C. ;
Lipsett, Pamela A. ;
Malani, Preeti N. ;
May, Larissa S. ;
Moran, Gregory J. ;
Neuhauser, Melinda M. ;
Newland, Jason G. ;
Ohl, Christopher A. ;
Samore, Matthew H. ;
Seo, Susan K. ;
Trivedi, Kavita K. .
CLINICAL INFECTIOUS DISEASES, 2016, 62 (10) :E51-E77
[7]   Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and Clostridium difficile infection: a systematic review and meta-analysis [J].
Baur, David ;
Gladstone, Beryl Primrose ;
Burkert, Francesco ;
Carrara, Elena ;
Foschi, Federico ;
Doebele, Stefanie ;
Tacconelli, Evelina .
LANCET INFECTIOUS DISEASES, 2017, 17 (09) :990-1001
[8]   Meta-Analysis of Antibiotics and the Risk of Community-Associated Clostridium difficile Infection [J].
Brown, Kevin A. ;
Khanafer, Nagham ;
Daneman, Nick ;
Fisman, David N. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (05) :2326-2332
[9]   Electronic antibiotic stewardship - reduced consumption of broad-spectrum antibiotics using a computerized antimicrobial approval system in a hospital setting [J].
Buising, K. L. ;
Thursky, K. A. ;
Robertson, M. B. ;
Black, J. F. ;
Street, A. C. ;
Richards, M. J. ;
Brown, G. V. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2008, 62 (03) :608-616
[10]   Risk of Severe Dysglycemia Among Diabetic Patients Receiving Levofloxacin, Ciprofloxacin, or Moxifloxacin in Taiwan [J].
Chou, Hsu-Wen ;
Wang, Jiun-Ling ;
Chang, Chia-Hsuin ;
Lee, Jen-Jyh ;
Shau, Wen-Yi ;
Lai, Mei-Shu .
CLINICAL INFECTIOUS DISEASES, 2013, 57 (07) :971-980